BPC-157
Also known as: Body Protection Compound-157, Bepecin, PL 14736, Gastric Pentadecapeptide BPC-157
Overview
BPC-157 is a synthetic 15-amino acid peptide derived from a naturally occurring protective protein isolated from human gastric juice. Originally characterized by researchers at the University of Zagreb, it has become one of the most extensively studied research peptides across a broad range of preclinical models. Its exceptional stability in gastric acid allows oral administration, distinguishing it from many therapeutic peptides that require injection.
Mechanism of Action
BPC-157 acts as a pleiotropic cytoprotective peptide, modulating multiple signaling networks simultaneously rather than targeting a single receptor. Key pathways include: VEGFR2 activation driving angiogenesis via the Akt-eNOS cascade; PI3K/AKT pro-survival pathway upregulation; focal adhesion kinase (FAK)-paxillin complex activation enabling cell migration; JAK-2 activation promoting cell survival and growth hormone receptor sensitization; ERK1/2 pathway stimulation promoting cell division; and nitric oxide system modulation. It also upregulates VEGF expression, regulates tight junction proteins (ZO-1), and induces heat shock proteins (HSP70/90) for GI cytoprotection.
Potential Benefits
- Accelerated wound healing and tissue repair across multiple tissue types
- Gastrointestinal protection and gut barrier integrity support
- Musculoskeletal healing including tendons, ligaments, and bone
- Neuroprotective effects in CNS and spinal cord injury models
- Anti-inflammatory activity via prostaglandin and NO modulation
- Angiogenesis promotion to improve blood supply to damaged tissues
- Cytoprotective effects against organ ischemia-reperfusion injury
- Potential gastroprotection and IBD symptom reduction
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 200-500 mcg/day |
| Beginner | 200-250 mcg/day |
| Intermediate | 500 mcg/day |
| Advanced | 750-1000 mcg/day |
| Cycle Duration | 4-8 weeks |
| Cycle Off | 4 weeks |
Can be dosed once or twice daily. Oral administration uses higher doses (1-2 mg/day). Inject near injured tissue for localized effects when possible.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High
Most common research route; inject near site of injury for localized effect
Intramuscular Injection High
Comparable to subcutaneous; useful for muscle injuries
Oral Moderate
Unique among peptides for oral stability; requires 2-5x higher dose for systemic effect; effective for GI tract issues
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving BPC-157:
Recovery Stack
Enhanced tissue repair and systemic recovery
BPC-157 provides local cytoprotection and angiogenesis while TB-500 drives systemic anti-inflammatory and actin remodeling. The most popular peptide healing combination.
Gut Healing Stack
GI tract repair, inflammation control, and antimicrobial support
Orally administered BPC-157 combined with KPV and LL-37 targets intestinal permeability, IBD-like symptoms, and mucosal integrity.
Tendon & Ligament Stack
Accelerated tendon, ligament, and connective tissue repair
GHK-Cu adds collagen synthesis and TGF-β regulation; all three work on different but complementary repair pathways.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 5mg, 10mg |
|---|---|
| BAC Water | 2ml per 5mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Shelf Life | 28-30 days refrigerated; do not freeze reconstituted solution |
Need exact syringe measurements?
Amino Acid Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
Side Effects & Safety
- Generally well-tolerated in animal models
- Nausea possible with subcutaneous injection
- No serious adverse events reported in available studies
- Long-term human safety data lacking
Synergistic Compounds
The following compounds have been studied alongside BPC-157 for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]
- [object Object]
- [object Object]